Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Wheat allergy immunotherapy - DBV Technologies

Next Previous
Search
Drug Profile

Wheat allergy immunotherapy - DBV Technologies

Alternative Names: Wheat Oral Immunotherapy; Wheat-OIT

Latest Information Update: 31 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DBV Technologies
  • Class Food allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Food hypersensitivity

Most Recent Events

  • 27 Oct 2020 Discontinued - Phase-I/II for Food hypersensitivity (In adolescents, In children, In adults) in USA (PO) (DBV Technologies pipeline, October 2020)
  • 13 Apr 2017 DBV Technologies completes a phase I/II trial in Food allergy (In children, In adolescents, In adults) in USA (PO) (NCT01980992)
  • 03 Mar 2017 Efficacy and adverse events data from a clinical trial in Food allergy presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2017)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top